Apellis Pharmaceuticals Announces FDA Approval Of EMPAVELI Injector - Quick Facts

(RTTNews) - Apellis Pharmaceuticals, Inc. (APLS) announced the FDA has approved the EMPAVELI Injector. It is a single-use, on-body device designed to enhance self-administration of EMPAVELI, which is approved for adults with paroxysmal nocturnal hemoglobinuria.

The company noted that the EMPAVELI Injector is the first high-volume, subcutaneous on-body delivery system which features several advances to streamline self-administration. It is developed in collaboration with Enable Injections, based on the enFuse Syringe Transfer System.

EMPAVELI is a targeted C3 therapy designed to regulate excessive activation of the complement cascade, part of the body's immune system, which can lead to the onset and progression of many serious diseases.

For More Such Health News, visit rttnews.com.